This information is intended for US healthcare professionals.

Prescribing Information
Important Safety Information
Patient Site
Patient Site

Full Prescribing Information

1Indications and Usage
2Dosage and Administration
3Dosage Forms and Strengths
4Contraindications
5 Warnings and Precautions
6Adverse Reactions
7Drug Interactions
8Use in Specific Populations

10 Overdosage
11 Description
12 Clinical Pharmacology
13 Nonclinical Toxicology
14 Clinical Studies
16 How Supplied/Storage and Handling
17 Patient Counseling Information

Co-pay Support Injectable PrEP Option

Why DESCOVY^®?
- Renal & Bone Over Time
- TAF Pharmacology
Efficacy Data
- HIV Incidence Rate
- Seroconversions
Renal & Bone Data
- Renal Data
- Bone Data
Safety Data & Tolerability
Starting DESCOVY^®
- Dosing & Product Offerings
- Initiating DESCOVY^® & Follow-up Visits
Access & Resources

Patient Site
Important Safety Information

Site map

Home
Why DESCOVY^®?
- Renal & Bone Over Time
- TAF Pharmacology
Efficacy Data
- HIV Incidence Rate
- Seroconversions
Renal & Bone Data
- Renal Data
- Bone Data
Safety Data & Tolerability
- Adverse Reactions & Discontinuations
- Contraindications & DDIs
- Warnings
Starting DESCOVY^®
- Dosing & Product Offerings
- Initiating DESCOVY^® & Follow-up Visits
Access & Resources
- Co-pay & Advancing Access^®
- Resources
- Expert Insights
- Register for Updates
- FAQs

IMPORTANT SAFETY INFORMATION

Collapse

INDICATION & LIMITATION OF USE

INDICATION & LIMITATION OF USE

INDICATION & LIMITATION OF USE

DESCOVY^® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.

Limitation of Use: DESCOVY FOR PrEP^® is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

Tap for Important Safety Information, including BOXED WARNING about the risk of drug resistance in undiagnosed early HIV-1 infection and post-treatment acute exacerbation of hepatitis B.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: RISK OF DRUG RESISTANCE WITH USE OF DESCOVY FOR PrEP^® IN UNDIAGNOSED EARLY HIV-1 INFECTION and POST-TREATMENT ACUTE EXACERBATION OF HEPATITIS B

DESCOVY FOR PrEP must be prescribed only to individuals confirmed to be HIV negative immediately prior to initiation and at least every 3 months during use. Drug-resistant HIV-1 variants have been identified with use of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for HIV-1 PrEP following undetected acute HIV-1 infection. Do not initiate if signs or symptoms of acute HIV-1 infection are present unless HIV-negative status is confirmed
Severe acute exacerbations of hepatitis B have been reported in individuals infected with hepatitis B virus (HBV) who discontinued products containing FTC and/or TDF and may occur with discontinuation of DESCOVY^®. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in individuals with HBV who discontinue DESCOVY. If appropriate, anti-hepatitis B therapy may be warranted

Contraindication

DESCOVY FOR PrEP is contraindicated in individuals with unknown or positive HIV status

Warnings and precautions

Comprehensive management to reduce risks:
- Use DESCOVY FOR PrEP to reduce the risk of HIV-1 infection as part of a comprehensive strategy that includes adherence to daily dosing and safer sex practices, including condoms, to reduce the risk of sexually transmitted infections (STIs)
- HIV-1 risk factors: Behavioral, biological, or epidemiologic HIV-1 risk factors may include, but are not limited to: condomless sex, past or current STIs, self-identified HIV risk, having sexual partners of unknown HIV-1 viremic status, or sexual activity in a high-prevalence area or network
- Reduce STI risk: Counsel on the use of STI prevention measures (e.g., consistent and correct condom use, knowledge of partner’s HIV-1 viremic status, regular testing for STIs)
- Reduce potential for drug resistance: Only prescribe DESCOVY FOR PrEP to individuals confirmed to be HIV negative immediately prior to initiation, at least every 3 months while taking DESCOVY, and upon an STI diagnosis. HIV-1 resistance substitutions may emerge in individuals with undetected HIV-1 infection who are taking only DESCOVY because DESCOVY alone is not a complete regimen for treating HIV-1
- Some HIV tests may not detect acute HIV infection. Prior to initiating DESCOVY FOR PrEP, ask individuals about potential recent exposure events. If recent (<1 month) exposures are reported or suspected, or symptoms of acute HIV infection (e.g., fever, fatigue, myalgia, skin rash) are present, confirm HIV-negative status with a test approved by the FDA for use in the diagnosis of acute HIV infection
- If HIV-1 infection is suspected or if symptoms of acute infection are present while taking DESCOVY FOR PrEP, convert the DESCOVY FOR PrEP regimen to a complete HIV treatment regimen until HIV-negative status is confirmed by a test approved by the FDA for use in the diagnosis of acute HIV infection
- Counsel on adherence: Counsel individuals to strictly adhere to daily dosing, as efficacy is strongly correlated with adherence. Some individuals, such as adolescents, may benefit from more frequent visits and counseling
New onset or worsening renal impairment: Postmarketing cases of renal impairment, including acute renal failure, proximal renal tubulopathy (PRT), and Fanconi syndrome have been reported with tenofovir alafenamide (TAF)-containing products. Do not initiate DESCOVY in individuals with estimated creatinine clearance (CrCl) <30 mL/min. Individuals with impaired renal function and/or taking nephrotoxic agents (including NSAIDs) are at increased risk of renal-related adverse reactions. Discontinue DESCOVY in individuals who develop clinically significant decreases in renal function or evidence of Fanconi syndrome. Monitor renal function in all individuals (see Dosage and Administration section)
Lactic acidosis and severe hepatomegaly with steatosis: Fatal cases have been reported with the use of nucleoside analogs, including FTC and TDF. Discontinue use if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity develop, including hepatomegaly and steatosis in the absence of marked transaminase elevations

Adverse reactions

Most common adverse reactions (≥2%) in the DESCOVY FOR PrEP clinical trial were diarrhea, nausea, headache, fatigue, and abdominal pain

Drug interactions

Prescribing information: Consult the full Prescribing Information for DESCOVY for more information, warnings, and potentially significant drug interactions, including clinical comments
Metabolism: Drugs that inhibit P-gp can increase the concentrations of TAF, a component of DESCOVY. Drugs that induce P-gp can decrease the concentrations of TAF, which may lead to loss of efficacy
Drugs affecting renal function: Coadministration of DESCOVY with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of FTC and tenofovir and the risk of adverse reactions

Dosage and administration

Dosage: One tablet (emtricitabine 200 mg/tenofovir alafenamide 25 mg) taken once daily with or without food
HIV screening: Test for HIV-1 infection immediately prior to initiating, at least every 3 months during use, and upon diagnosis of an STI (see Warnings and Precautions section)
HBV screening: Test for HBV infection prior to or when initiating DESCOVY
Renal impairment and monitoring: Not recommended in individuals with CrCl <30 mL/min. Prior to or when initiating DESCOVY, and during use on a clinically appropriate schedule, assess serum creatinine, CrCl, urine glucose, and urine protein in all individuals. In individuals with chronic kidney disease, assess serum phosphorus

Please see full Prescribing Information for DESCOVY FOR PrEP, including BOXED WARNING.

You are leaving the DESCOVY FOR PrEP^® website

LEAVE SITE GO BACK

You are leaving the DESCOVY FOR PrEP^® website

You have clicked on a link for a third-party site that Gilead does not own. Gilead is not responsible for any content or services available on this third-party site.

LEAVE SITE GO BACK

Terms of Use
Privacy Policy
Consumer Health Data Privacy Policy
Contact Us
Site Map
Prescribing Information
Your Privacy Choices

The content on this site may not apply to non-US audiences as regulatory control, legal requirements, and/or medical practices may vary in other countries.

DESCOVY, the DESCOVY Logo, DESCOVY FOR PrEP, the DESCOVY FOR PrEP Logo, the DESCOVY Blue Pill Design, TRUVADA, the TRUVADA Blue Pill Design, GSI, ADVANCING ACCESS, GILEAD, and the GILEAD Logo are trademarks of Gilead Sciences, Inc., or its related companies. All other marks referenced herein are the property of their respective owners.

©2026 Gilead Sciences, Inc. All rights reserved. US-DVYP-0861 09/26